Literature DB >> 26121318

MicroRNAs in the pathobiology of sarcomas.

Anne E Sarver1, Subbaya Subramanian1,2.   

Abstract

Sarcomas are a rare and heterogeneous group of tumors. The last decade has witnessed extensive efforts to understand the pathobiology of many aggressive sarcoma types. In parallel, we have also begun to unravel the complex gene regulation processes mediated by microRNAs (miRNAs) in sarcomas and other cancers, discovering that microRNAs have critical roles in the majority of both oncogenic and tumor suppressor signaling networks. Expression profiles and a greater understanding of the biologic roles of microRNAs and other noncoding RNAs have considerably expanded our current knowledge and provided key pathobiological insights into many sarcomas, and helped identify novel therapeutic targets. The limited number of sarcoma patients in each sarcoma type and their heterogeneity pose distinct challenges in translating this knowledge into the clinic. It will be critical to prioritize these novel targets and choose those that have a broad applicability. A small group of microRNAs have conserved roles across many types of sarcomas and other cancers. Therapies that target these key microRNA-gene signaling and regulatory networks, in combination with standard of care treatment, may be the pivotal component in significantly improving treatment outcomes in patients with sarcoma or other cancers.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26121318     DOI: 10.1038/labinvest.2015.81

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  130 in total

1.  A DNA microarray system for analyzing complex DNA samples using two-color fluorescent probe hybridization.

Authors:  D Shalon; S J Smith; P O Brown
Journal:  Genome Res       Date:  1996-07       Impact factor: 9.043

2.  miR-16 inhibits cell proliferation by targeting IGF1R and the Raf1-MEK1/2-ERK1/2 pathway in osteosarcoma.

Authors:  Lei Chen; Qing Wang; Guo-dong Wang; Hua-song Wang; Yong Huang; Xi-ming Liu; Xian-hua Cai
Journal:  FEBS Lett       Date:  2013-03-15       Impact factor: 4.124

Review 3.  The functions and regulation of the PTEN tumour suppressor.

Authors:  Min Sup Song; Leonardo Salmena; Pier Paolo Pandolfi
Journal:  Nat Rev Mol Cell Biol       Date:  2012-04-04       Impact factor: 94.444

4.  Characterization of sarcomas by means of gene expression.

Authors:  Keith M Skubitz; Amy P N Skubitz
Journal:  J Lab Clin Med       Date:  2004-08

Review 5.  The P53 pathway: what questions remain to be explored?

Authors:  A J Levine; W Hu; Z Feng
Journal:  Cell Death Differ       Date:  2006-06       Impact factor: 15.828

Review 6.  RNA-Seq: a revolutionary tool for transcriptomics.

Authors:  Zhong Wang; Mark Gerstein; Michael Snyder
Journal:  Nat Rev Genet       Date:  2009-01       Impact factor: 53.242

7.  Suppression of non-small cell lung tumor development by the let-7 microRNA family.

Authors:  Madhu S Kumar; Stefan J Erkeland; Ryan E Pester; Cindy Y Chen; Margaret S Ebert; Phillip A Sharp; Tyler Jacks
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-28       Impact factor: 11.205

8.  Let-7a is a direct EWS-FLI-1 target implicated in Ewing's sarcoma development.

Authors:  Claudio De Vito; Nicolo Riggi; Mario-Luca Suvà; Michalina Janiszewska; Janine Horlbeck; Karine Baumer; Paolo Provero; Ivan Stamenkovic
Journal:  PLoS One       Date:  2011-08-10       Impact factor: 3.240

Review 9.  MicroRNA regulons in tumor microenvironment.

Authors:  H I Suzuki; A Katsura; H Matsuyama; K Miyazono
Journal:  Oncogene       Date:  2014-08-18       Impact factor: 9.867

Review 10.  Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.

Authors:  James A McCubrey; Linda S Steelman; William H Chappell; Stephen L Abrams; Giuseppe Montalto; Melchiorre Cervello; Ferdinando Nicoletti; Paolo Fagone; Grazia Malaponte; Maria C Mazzarino; Saverio Candido; Massimo Libra; Jörg Bäsecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Michele Milella; Agostino Tafuri; Lucio Cocco; Camilla Evangelisti; Francesca Chiarini; Alberto M Martelli
Journal:  Oncotarget       Date:  2012-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.